AI Article Synopsis

  • GluN2B activation of NMDA receptors is linked to neurodegenerative disorders like Parkinson's, Alzheimer's, and stroke, making NMDA receptor antagonists potential treatments.
  • A study explored thirty GluN2B NMDA receptor antagonists using computer-assisted drug design, identifying C13 and C22 as promising non-toxic candidates with strong brain absorption.
  • Molecular docking revealed that C22 and C13 interact effectively with NMDA receptors, demonstrating stability and safety, positioning them as recommended anti-stroke therapeutic drugs.

Article Abstract

GluN2B-induced activation of NMDA receptors plays a key function in central nervous system (CNS) disorders, including Parkinson, Alzheimer, and stroke, as it is strongly involved in excitotoxicity, which makes selective NMDA receptor antagonists one of the potential therapeutic agents for the treatment of neurodegenerative diseases, especially stroke. The present study aims to examine a structural family of thirty brain-penetrating GluN2B N-methyl-D-aspartate (NMDA) receptor antagonists, using virtual computer-assisted drug design (CADD) to discover highly candidate drugs for ischemic strokes. Initially, the physicochemical and ADMET pharmacokinetic properties confirmed that C13 and C22 compounds were predicted as non-toxic inhibitors of CYP2D6 and CYP3A4 cytochromes, with human intestinal absorption (HIA) exceeding 90%, and designed to be as efficient central nervous system (CNS) agents due to the highest probability to cross the blood-brain barrier (BBB). Compared to ifenprodil, a co-crystallized ligand complexed with the transport protein encoded as 3QEL.pdb, we have noticed that C13 and C22 chemical compounds were defined by good ADME-Toxicity profiles, meeting Lipinski, Veber, Egan, Ghose, and Muegge rules. The molecular docking results indicated that C22 and C13 ligands react specifically with the amino acid residues of the NMDA receptor subunit GluN1 and GluN2B. These intermolecular interactions produced between the candidate drugs and the targeted protein in the B chain remain stable over 200 nanoseconds of molecular dynamics simulation time. In conclusion, C22 and C13 ligands are highly recommended as anti-stroke therapeutic drugs due to their safety and molecular stability towards NMDA receptors.Communicated by Ramaswamy H. Sarma.

Download full-text PDF

Source
http://dx.doi.org/10.1080/07391102.2023.2232024DOI Listing

Publication Analysis

Top Keywords

nmda receptor
16
receptor antagonists
12
anti-stroke therapeutic
8
therapeutic agents
8
central nervous
8
nervous system
8
system cns
8
candidate drugs
8
c13 c22
8
c22 c13
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!